Holen Sie sich die Stockscreener-App
0.7308
4.40%
0.0308
Vorhandelsmarkt:
.64
-0.0908
-12.42%
Schlusskurs vom Vortag:
$0.70
Offen:
$0.7087
24-Stunden-Volumen:
7.54M
Relative Volume:
0.26
Marktkapitalisierung:
$44.21M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-12.89M
KGV:
-0.2889
EPS:
-2.53
Netto-Cashflow:
$-11.95M
1W Leistung:
+11.06%
1M Leistung:
+103.17%
6M Leistung:
-34.75%
1J Leistung:
-48.17%
1-Tages-Spanne:
$0.6681
$0.735
1-Wochen-Bereich:
$0.6681
$0.87
52-Wochen-Spanne:
$0.1634
$2.3099
Plus Therapeutics Inc Stock (PSTV) Company Profile
Firmenname
Plus Therapeutics Inc
Sektor
Branche
Telefon
737.255.7194
Adresse
4200 MARATHON BLVD., AUSTIN, TX
Vergleichen Sie PSTV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.7308 | 42.34M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-17 | Eingeleitet | D. Boral Capital | Buy |
| 2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-10-16 | Eingeleitet | Maxim Group | Buy |
Plus Therapeutics Inc Aktie (PSTV) Neueste Nachrichten
Plus Therapeutics Approves Key Proposals at Annual Meeting - MSN
Plus Therapeutics Plunges 5.43% on Disappointing Q1 Earnings - AInvest
Why Plus Therapeutics Inc. stock attracts strong analyst attentionOptimized Capital Rotation Picks - kangso.co.kr
RSI Crosses Above 30 for Plus Therapeutics Inc. — Reversal in SightReversal Alert Based on RSI Indicator Confirmed - beatles.ru
Plus Therapeutics PSTV 2025Q2 Earnings Preview Downside Ahead on Declining Revenue Expectations - AInvest
Plus Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Arch Therapeutics Inc. (ARTH) Product Pipeline Analysis, 2025 Update - GlobeNewswire Inc.
Plus Therapeutics, Inc. shares rise 2.37% premarket after Almirall and Absci expand AI Drug Creation collaboration. - AInvest
Plus Therapeutics Surges 17.46% on Breakthrough FDA Clearance and Strategic Funding Boost – What’s Next for PSTV? - AInvest
Plus Therapeutics shares rise 3.34% premarket after announcing a dose escalation phase 1 study for 186RNL. - AInvest
How does Plus Therapeutics Inc. generate profit in a changing economyHarness the power of proven investment plans - Jammu Links News
What is the dividend policy of Plus Therapeutics Inc. stockCapitalize on fast-moving stock opportunities - Jammu Links News
What is the risk reward ratio of investing in Plus Therapeutics Inc. stockUnlock real-time stock alerts for quick profits - Jammu Links News
What institutional investors are buying Plus Therapeutics Inc. stockConsistent triple-digit returns - Jammu Links News
What makes Plus Therapeutics Inc. stock price move sharplyFree High-Return Strategy Alerts - Jammu Links News
What analysts say about Plus Therapeutics Inc. stockGet timely advice on market trends - Jammu Links News
What drives Plus Therapeutics Inc. stock priceExtraordinary earning power - Jammu Links News
How strong is Plus Therapeutics Inc. company’s balance sheetTop Growth Trend Scanner With High Returns - jammulinksnews.com
Published on: 2025-08-01 22:18:13 - metal.it
Plus Therapeutics (PSTV.O) Surges 16.5% — What's Behind the Sharp Move? - AInvest
Plus Therapeutics’ Innovative Study on Rhenium-186 NanoLiposome for Cancer Metastases - TipRanks
What are analysts’ price targets for Plus Therapeutics Inc. in the next 12 monthsStock Strategy Recommendation From AI Tools - jammulinksnews.com
Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic - GlobeNewswire
Plus Therapeutics (PSTV) to Introduce CNSide Diagnostics in Texas by August 2025 - GuruFocus
Plus Therapeutics Provides US Launch Update for its CNSide® Diag - GuruFocus
Revolutionary CNS Cancer Test With 92% Accuracy Launches at Major Texas Cancer Centers - Stock Titan
Is Plus Therapeutics Inc. stock overvalued or undervaluedReal Time Watchlist With Proven Results - jammulinksnews.com
Plus Therapeutics (PSTV.O) Plunges 13%: Unpacking the Intraday Shock - AInvest
Institutional Tools Highlight Unusual Flow in Plus Therapeutics Inc.Watchlist for Smart Swing Trading Updated - metal.it
Does Plus Therapeutics Inc. stock perform well during market downturnsBuild wealth steadily with proven investment techniques - jammulinksnews.com
Why is Plus Therapeutics Inc. stock attracting strong analyst attentionAmplify your gains with low-risk picks - Jammu Links News
What catalysts could drive Plus Therapeutics Inc. stock higher in 2025Unlock rapid growth potential in your portfolio - jammulinksnews.com
How volatile is Plus Therapeutics Inc. stock compared to the marketConsistent wealth multiplication - jammulinksnews.com
Published on: 2025-07-27 20:49:15 - jammulinksnews.com
Healthcare Stocks Move in Intrday Session: Gainers and Losers - AInvest
Should I buy Plus Therapeutics Inc. stock before earningsRecord-setting profit potential - jammulinksnews.com
Finanzdaten der Plus Therapeutics Inc-Aktie (PSTV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.91%
3.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):